



Mirati Therapeutics  
Investor Relations Department  
9393 Towne Centre Drive  
Suite 200 Tel.: 858.332.3410  
San Diego, CA 92121  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: MRTX

Last Trade:	3.40
Trade Time:	4:00 PM ET May 23, 2017
Change:	-0.25 <span style="color: red;">↓</span> (-6.849%)
Day Range	3.35 - 3.70
52-Week Range	3.10 - 19.25
Volume	122,851


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

*Mirati Therapeutics is a targeted oncology company developing therapeutics for precisely defined patient populations. The Mirati team is using a blueprint proven by their prior work for developing potential breakthrough therapies with accelerated development paths. Mirati is currently advancing three drug candidates through clinical development for multiple oncology indications. Mirati trades on the NASDAQ under the ticker symbol "MRTX."*

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- [May 4, 2017  
Mirati Therapeutics Reports First Quarter 2017 Financial Results](#)
- [Mar 9, 2017  
Mirati Therapeutics Reports Financial Results And Provides Business Update For The Fourth Quarter And Full Year 2016](#)
- [Feb 13, 2017  
Mirati Therapeutics To Present At Leerink Partners 6th Annual Global Healthcare Conference](#)
- [Jan 11, 2017  
Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares](#)
- [Jan 6, 2017  
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock](#)

## Financials [\[ View all \]](#)

- [First Quarter Financial Results](#)
- [Mar 9, 2017  
Annual Report \(10-K\)](#)
- [Apr 20, 2017  
Proxy Statement \(DEF 14A\)](#)
- [May 4, 2017  
Quarterly Report \(10-Q\)](#)
- [Nov 3, 2016  
Quarterly Report \(10-Q\)](#)
- [Aug 4, 2016  
Quarterly Report \(10-Q\)](#)